The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

BACKGROUND: The phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising therapeutic target. AZD8186 (AstraZeneca) is a PI3Kβ/δ inhibitor, currently in phase 1 clinical trials. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET)...

Descripción completa

Detalles Bibliográficos
Autores principales: Maynard, Juliana, Emmas, Sally-Ann, Blé, Francois-Xavier, Barjat, Hervé, Lawrie, Emily, Hancox, Urs, Oakes, Deborah, Polanska, Urszula M., Barry, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980858/
https://www.ncbi.nlm.nih.gov/pubmed/27515445
http://dx.doi.org/10.1186/s13550-016-0220-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980858/
https://www.ncbi.nlm.nih.gov/pubmed/27515445
http://dx.doi.org/10.1186/s13550-016-0220-9

Ejemplares similares